FDA clears Legend Biotech's LB2501 CAR-T therapy for clinical trials
LEGN•The FDA cleared Legend Biotech's investigational new drug application for LB2501, a dual-targeting CD19/CD20 in vivo CAR-T therapy, supporting a planned US Phase 1/2 trial in relapsed or refractory B-cell malignancies.
1. Trial clearance
Legend Biotech received FDA clearance for its investigational new drug application for LB2501, a dual-targeting CD19/CD20 in vivo CAR-T therapy. The clearance supports a planned US Phase 1/2 trial in relapsed or refractory B-cell malignancies.
